Date published: 2026-4-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

FGF-10 Inhibitors

FGF-10 inhibitors represent a class of chemical compounds specifically designed to target and block the activity of fibroblast growth factor 10 (FGF-10). FGF-10 is a member of the fibroblast growth factor family, which plays a crucial role in various cellular processes, including cell proliferation, differentiation, and tissue development. These inhibitors are developed with the primary aim of modulating the FGF-10 signaling pathway, thereby impacting the downstream cellular responses influenced by this growth factor. The mechanism of action of FGF-10 inhibitors involves interfering with the binding of FGF-10 to its cognate receptor, typically fibroblast growth factor receptor 2b (FGFR2b). These inhibitors may operate through competitive binding at the receptor-binding site, preventing the interaction between FGF-10 and FGFR2b. Alternatively, they may disrupt downstream intracellular signaling events initiated by FGF-10 binding, ultimately inhibiting the transmission of proliferative and differentiative signals to target cells. By specifically targeting FGF-10 and its associated pathways, these inhibitors offer a means to modulate cellular responses in various contexts. Researchers are continually exploring the ability of FGF-10 inhibitors as valuable tools for elucidating the biology of FGF-10 and its role in various physiological and pathological processes, paving the way for a deeper understanding of cellular regulation and interventions in the future.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$37.00
$152.00
11
(1)

This compound is a pyrimidine analog, which can integrate into RNA and DNA, potentially disrupting normal cellular processes and leading to decreased expression of certain proteins including FGF-10.

Methotrexate

59-05-2sc-3507
sc-3507A
100 mg
500 mg
$94.00
$213.00
33
(5)

Methotrexate is a folate analog that inhibits dihydrofolate reductase, leading to reduced availability of tetrahydrofolate necessary for purine and thymidylate synthesis, possibly affecting FGF-10 expression.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin inhibits the mTOR pathway, which is involved in cell growth and protein synthesis, potentially leading to reduced expression of FGF-10.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib is a kinase inhibitor that may reduce FGF-10 expression by inhibiting downstream signaling pathways activated by FGF receptors.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Gefitinib is an EGFR tyrosine kinase inhibitor that could potentially downregulate FGF-10 expression by inhibiting EGFR-related signaling pathways.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

Erlotinib Hydrochloride is an EGFR tyrosine kinase inhibitor, and it may decrease FGF-10 expression by inhibiting signaling pathways associated with EGFR.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$138.00
$380.00
101
(4)

Cisplatin forms DNA adducts, leading to DNA damage and potentially affecting the expression of various genes, including FGF-10.

Hydroxyurea

127-07-1sc-29061
sc-29061A
5 g
25 g
$78.00
$260.00
18
(1)

Hydroxyurea inhibits ribonucleotide reductase, leading to reduced availability of deoxyribonucleotides and potential downregulation of FGF-10 expression.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Suberoylanilide Hydroxamic Acid is a histone deacetylase inhibitor that alters chromatin structure and gene expression, which could lead to decreased FGF-10 expression.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib inhibits the proteasome, affecting protein degradation and potentially leading to reduced FGF-10 expression.